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Taurine, a sulfur-containing amino acid, is a normal constituent of the human diet. Little is known of the pharmacokinetics of
taurine in man after oral administration. We studied the pharmacokinetics of 4g taurine in eight healthy male volunteers (median
age 27.5, range 22–45) following orally administration in the fasting state in the morning. Blood samples were taken at regular
intervalsandplasmataurineconcentrationwasmeasuredbyamodiﬁedHPLCmethod.Dataweresubjectedtononcompartmental
analysis. Maximum plasma taurine concentration (Cmax) was measured at 1.5 ± 0.6hr after administration as 86.1 ± 19.0mg/L
(0.69 ± 0.15mmol). Plasma elimination half-life (T1/2) and the ratio of clearance/bioavailability (Cl/F) were 1.0 ± 0.3hrand
21.1 ± 7.8L/hr, respectively. Since taurine is occasionally used in therapeutics as a medicine, the pharmacokinetics and eﬀects of
oral taurine in healthy volunteers would be useful in the future studies of taurine in pharmacology and nutrition.
1.Introduction
Taurine, a sulfur-containing amino acid, is a relatively
nontoxic substance and a normal constituent of the human
diet [1]. The diet provides most taurine either directly or
by synthesis in the liver and brain from methionine or
cysteine via cysteic acid or hypotaurine [2] or via cysteamine
in the heart and kidney. Taurine stabilises membranes,
modulates calcium transport, and is able to dissipate the
toxic eﬀects of hypochlorous acid (HOCl) by the formation
of the relatively stable taurochloramine molecule, generated
by myeloperoxidases from oxygen radicals. The ability of
taurine to conjugate with xenobiotics, retinoic acid, and bile
salts and its role as a major free amino acid in regulating the
osmolality of cells are also examples of protective functions
[3]. Obinata et al. showed ALT concentrations recovering in
children with fatty liver after 6-months treatment with oral
taurine administered daily [4]. Protective eﬀects of taurine
against arteriosclerosis [5], lung injury by oxidant gases [6],
deleterious eﬀects of various drugs such as tauromustine,
an antitumor agent, [7], hepatotoxicity of sulfolithocholate
[8], and its promotion of the recovery of leukocytes in
irradiated rats [9] have already been studied on animals. The
therapeutic eﬀects of taurine on epilepsy [10], ischemia [11],
obesity [12], diabetes [13], hypertension [14], Congestive
heart failure [15], noxious eﬀect of smoking [16], toxicity
of methotrexate [17] myocardial infarction [18], alcoholic
craving [19], and neurodegeneration in elderly [20]h a v e
also been reported. Taurine may protect membranes by
detoxiﬁcation of destructive compounds and/or by directly
preventing alterations in membrane permeability [21].Some
foods or drinks, for example, Red Bull energy drink [22],
boosters, eye drops, and eardrops, contain a considerable
amount of taurine [23]. Little is known of the pharma-
cokinetics of taurine in man after oral administration. Such
information is essential if a regimen for administration of
this agent to patients (e.g., after paracetamol poisoning)
is designed. A literature review revealed only one report
concerning the pharmacokinetics of taurine performed by
Zhang et al. [24] using 200mg IV injection form of taurine2 Journal of Amino Acids
in six patients with hypertension, but the paper was brief
and only available in mandarin. We therefore studied the
pharmacokinetics and eﬀects of oral taurine in healthy
volunteers that would be useful in the future studies of
taurine in pharmacology and nutrition
2.MaterialsandMethods
Eight healthy male volunteers (age between 22–45 year, med.
27.5 and weight between 69–122kg, med. 79.5kg) were
recruited from the general population after fully informed
written consent and after getting approval from the ethics
committee of Bro Taf Health Authority of Wales, UK. Each
taurine capsule contained 1000mg (0.008moL) taurine,
manufactured by Life Extension Foundation Buyers Club,
Inc (USA). Taurine 4g (32mmoL) was administered orally
to each volunteer in the fasting state in the morning.
Subjectswereasked to avoid taking anyproprietary medicine
including prescribed or recreational drugs, eating ﬁsh and
any seafood or dairy products, and drinking “Red-Bull” 24
hours before and 48 hours after the study. They were given
toast and jam with a cup of tea one hour after starting the
study and a normal meal without any seafood at 4hr of the
study. Blood samples were taken (3mL each time) at regular
intervals over the following times: 0, 0.5, 1, 1.5, 2, 2.5, 3,
3.5, 4, 5, 6, 7, and 8 hours and at 24 and 48 hours using
cannulae in the brachial vain and collected into heparinised
tubes. The samples were immediately centrifuged at 4◦C
at 3000rpm. Plasma was removed using a Pasteur pipette
and transferred into 5ml glass tubes and kept frozen at
−20◦C until analysis. Plasma taurine concentration was
measured by a modiﬁed HPLC method. This method was
sensitiveenough,toquantify150pg/mLanddetect50pg/mL
of taurine ranging normally between 65 and 179mmol/L
(8–22μg/mL) [25]. The pharmacokinetic parameters of
area under the concentration curve (AUC0–8h), maximum
concentration (Cmax), time of Cmax (Tmax), plasma half-
life (T1/2), volume of distribution (V), and the ratio of
clearance/bioavailability (Cl/F) were calculated using Win-
Nonlin (Version 1.5) software packages. The data were used
to develop a noncompartmental pharmacokinetic model,
which might be suitable for patient studies in the future.
Since plasma taurine concentration returned to endogenous
level after 8hr of study, the data after 8hr were ruled out
of the pharmacokinetic analysis. In addition, since this was
a study of kinetics of exogenously administered taurine,
baseline endogenous concentrations of taurine in plasma
(0.04 ± 0.0mmoL) were also excluded from the study.
Therefore, the changes in plasma taurine concentration from
baseline were calculated.
3. Results
Plasma taurine values from 0–48hr in eight healthy volun-
teers after administration of 4g taurine capsules are listed
in Table 1. Data showed that endogenous plasma taurine
concentrations before taking the taurine capsules ranged





















































Figure 1: Linear plot of mean plasma taurine levels (mmoL) in
















































































healthy volunteers following administration of 4g (32mmoL) oral
taurine.
to reach maximum concentration ranged from 1 to 2.5hr
(mean 1.5 ± 0.6hr) (absorption phase). The mean maxi-
mum plasma taurine concentration was 0.57 ± 0.05mmoL.
Plasma taurine concentrations returned to normal range at
8hr (elimination phase) (Figure 1).
Mean changes in plasma taurine concentrations from
baseline showed that the absorption phase for taurine
after oral administration of 4g taurine capsules took 1.5hr
to reach the peak concentration (0.53 ± 0.1mmoL) and
then returned to normal range (0.04 ± 0.0mmoL) in
6.5hr(Figure 1).Thepharmacokineticparametersoftaurine
after oral administration of 4g taurine capsules are shownJournal of Amino Acids 3
Table 1: Plasma taurine concentrations (mmoL) in eight healthy volunteers after administration of 4g (32mmoL) oral taurine.
Time (hr) Subjects Mean SEM
12345678
0 0.06 0.04 0.03 0.03 0.03 0.04 0.06 0.04 0.04 0.00
0.5 0.31 0.44 0.22 0.41 0.04 0.04 0.23 0.19 0.24 0.05
1 0.62 0.57 0.61 0.84 0.20 0.06 0.35 0.80 0.51 0.10
1.5 0.46 0.56 0.74 0.75 0.60 0.30 0.53 0.62 0.57 0.05
2 0.32 0.44 0.93 0.51 0.72 0.77 0.32 0.43 0.56 0.08
2.5 0.27 0.41 0.66 0.36 0.64 0.84 0.24 0.37 0.47 0.08
3 0.23 0.27 0.40 0.28 0.42 0.68 0.21 0.23 0.34 0.06
3.5 0.18 0.22 0.36 0.25 0.33 0.49 0.20 0.20 0.28 0.04
4 0.11 0.16 0.26 0.18 0.27 0.41 0.17 0.18 0.22 0.03
5 0.07 0.10 0.16 0.11 0.20 0.32 0.07 0.03 0.13 0.03
6 0.06 0.08 0.08 0.10 0.10 0.23 0.06 0.04 0.09 0.02
7 0.06 0.07 0.08 0.07 0.09 0.14 0.06 0.03 0.07 0.01
8 0.06 0.06 0.05 0.04 0.07 0.05 0.06 0.05 0.05 0.00
24 0.06 0.04 0.03 0.02 0.04 0.06 0.07 0.06 0.05 0.01
48 0.05 0.04 0.04 0.02 0.02 0.06 0.09 0.04 0.05 0.01
Table 2: Pharmacokinetic parameters of taurine after oral administration of 4g (32mmoL) taurine capsules.
Subjects Cmax (mg/L) Tmax (hr) AUC(0-8hr) (mg·hr/L) Ke (hr−1)T 1/2(hr) V (L) Cl/F (L/hr)
1 69.7 1 127.7 0.8 0.8 37.8 31.2
2 66.7 1 198.0 0.5 1.4 40.7 19.5
3 112.6 2 281.4 0.6 1.1 22.1 14.0
4 100.4 1 235.0 0.6 1.1 26.8 16.9
5 86.1 2 232.0 0.5 1.4 32.5 16.6
6 99.5 2.5 284.5 0.7 1 19.8 14.0
7 59.0 1.5 116.0 1.0 0.7 34.8 34.4
8 94.8 1.0 175.9 0.9 0.8 25.1 22.2
Mean 86.1 1.5 206.3 0.7 1.0 30.0 21.1
SD 19.0 0.6 63.9 0.2 0.3 7.6 7.8
Range 59.0–112.6 1–2.5 116.0–284.5 0.5–1.0 0.7–1.4 19.8–40.7 14.0–34.4
in Table 2. Plasma taurine concentration peaked to 59.0–
112.6mg/L (mean 86.1 ± 19.0) at 1–2.5hr of study, plasma
elimination half-life ranged from 0.7 to 1.4hr (mean 1.0
± 0.3), volume of distribution ranged from 19.8 to 40.7L
(mean 30.0 ± 7.6), ratio of clearance/bioavailability (Cl/F)
ranged from 14.0 to 34.4L/hr (mean 21.1 ± 7.8), and area
under curve between 0–8hr (AUC) ranged from 116.0 to
284.5mg·hr/L (mean 206.3 ± 63.9).
4. Discussion
Taurine has already been used intravenously in humans in
doses of up to 5g [26] and 2–6g/day orally for a period of
6 months in children with fatty liver [4] without any toxic
sideeﬀect.Inthehumanadult,aboutone-fourthofbileacids
are conjugated with taurine and a small fraction of taurine
is also converted to isethionate by either bacterial or tissue
enzymes and may be converted in part to sulphate, CO2,
water, and ammonia, the last being converted to urea [27].
Total body taurine is regulated by the kidney. Taurine is a
major urinary amino acid in humans because the capacity
o fr e n a lu p t a k ei sl o w[ 2, 28]. Daily taurine losses in urine
are diet-dependent but generally range from 65 to 250mg
(0.5–2.0mmoL) [27]. With few exceptions, animal [2]a n d
human [15] studies have demonstrated that taurine, even in
high doses, is generally free of any serious adverse eﬀects.
In the present study, no signiﬁcant change in the systolic or
diastolic blood pressure and pulse rate was observed during
the study and the volunteers had no complaint during the
study. In the present study, data showed that oral taurine was
absorbed from the gastrointestinal tract 1–2.5hr following
administration and then eliminated from plasma by ﬁrst
order kinetics. Even though the volunteers had been asked
to avoid eating anything before coming to the trial, two
subjects (3 and 6), whose absorption phase took 2 and 2.5hr,
respectively, may not have taken the drug with an empty
stomach (Figure 2).4 Journal of Amino Acids
Plasma taurine returned to endogenous concentrations
after 6–8hr of study. Therefore, there was no need to follow
up the drug in plasma after 8hr.
A literature review revealed only one report concerning
the pharmacokinetics of taurine [24]. Zhang et al. studied
the pharmacokinetics of an IV injection of a 200mg bolus
dose on six hypertensive human patients and six healthy
volunteers. Plasma half-life and volume of distribution of
taurine in Zhang et al.’s was 3.85 ± 0.05min and 9.6 ±
3.2L, respectively. However, they only followed the plasma
taurine concentrations for 20min, and therefore, they were
probably examining an alpha phase which was obscured
by the absorption phase for taurine after oral absorption.
Further studies are necessary to elucidate the optimum dose
of oral taurine for protecting cells against toxic agents in
human.
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